Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393341 · ClinicalTrials.gov registry record
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
A clinical trial of Breast Cancer Stage II and Breast Cancer Stage I, sponsored by Indiana University School of Medicine.
- Completed
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT00393341: Completed study of Breast Cancer Stage II and Breast Cancer Stage I, sponsored by Indiana University School of Medicine.
NCT00393341 is a study of Breast Cancer Stage II and Breast Cancer Stage I that has completed, run by Indiana University School of Medicine. The registered enrollment target is 68 participants, below the 179-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393341, a study of Breast Cancer Stage II and Breast Cancer Stage I, has completed, sponsored by Indiana University School of Medicine.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose to quantitate endothelial progenitor cells (EPCs) in early and advanced breast cancer patients. Peripheral blood will be drawn from the eligible patients. Different type of EPCs will be isolated from the blood and quantitated.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-08 |
What the finished NCT00393341 record still lists
NCT00393341 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 179-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT00393341 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00393341 about?
NCT00393341 is a clinical study titled "Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer". We propose to quantitate endothelial progenitor cells (EPCs) in early and advanced breast cancer patients. Peripheral blood will be drawn from the eligible patients. Different type of EPCs will be isolated from the blood and quantitated.
What is the current status of trial NCT00393341?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2006-10. Estimated completion is 2009-08.
What conditions does trial NCT00393341 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage I, Breast Cancer Stage IV.
What interventions are being tested in trial NCT00393341?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT00393341?
This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393341 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00393341's enrollment target sits among peer trials
68 14th of 22 higher than 9 of 22 other Breast Cancer Stage II trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Stage II trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING · Phase 2
-
Optimizing Surgical Decisions in Young Adults With Breast Cancer
RECRUITING · NA
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia